161 related articles for article (PubMed ID: 15478578)
1. Current topics in bone metastases.
ONS News; 2004; 19(9 Suppl):35-6. PubMed ID: 15478578
[TBL] [Abstract][Full Text] [Related]
2. Metastatic bone disease and tumour-induced hypercalcaemia: treatment options.
Heatley S
Int J Palliat Nurs; 2004 Jan; 10(1):41-6. PubMed ID: 14966444
[TBL] [Abstract][Full Text] [Related]
3. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Saba N; Khuri F
Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
[TBL] [Abstract][Full Text] [Related]
4. [Bone metastases in lung cancer].
Tsuya A; Fukuoka M
Clin Calcium; 2008 Apr; 18(4):455-9. PubMed ID: 18379026
[TBL] [Abstract][Full Text] [Related]
5. [Symptom with bone metastasis--bone pain, fracture, hypercalcemia].
Toyoshi H
Nihon Rinsho; 2007 Jan; 65(1):76-81. PubMed ID: 17233419
[TBL] [Abstract][Full Text] [Related]
6. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
7. Metastatic bone disease in the era of bone-targeted therapy: clinical impact.
Ibrahim T; Farolfi A; Mercatali L; Ricci M; Amadori D
Tumori; 2013; 99(1):1-9. PubMed ID: 23548992
[TBL] [Abstract][Full Text] [Related]
8. Bone metastases, general and clinical issues.
Greco C; Forte L; Erba P; Mariani G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):337-52. PubMed ID: 21738111
[TBL] [Abstract][Full Text] [Related]
9. Managing skeletal related events resulting from bone metastases.
Wilkinson AN; Viola R; Brundage MD
BMJ; 2008 Nov; 337():a2041. PubMed ID: 18981017
[No Abstract] [Full Text] [Related]
10. Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Diel IJ; Solomayer EF; Bastert G
Clin Breast Cancer; 2000 Apr; 1(1):43-51. PubMed ID: 11899389
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases--the clinical problem.
Rubens RD
Eur J Cancer; 1998 Feb; 34(2):210-3. PubMed ID: 9741323
[No Abstract] [Full Text] [Related]
12. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
13. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.
Carter JA; Ji X; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):483-96. PubMed ID: 23862654
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiology and clinical features of bone metastases].
Cvitkovic F; Mouret-Fourme E
Bull Cancer; 2013 Nov; 100(11):1073-81. PubMed ID: 24169223
[TBL] [Abstract][Full Text] [Related]
15. [Bone metastases].
Jensen AB; Kamby C; Hansen B; Keller J
Ugeskr Laeger; 2007 Oct; 169(44):3753-6. PubMed ID: 18028842
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of bone metastases.
Reich CD
Clin J Oncol Nurs; 2003; 7(6):641-6. PubMed ID: 14705479
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases from advanced cancers: clinical implications and treatment options.
Fitch M; Maxwell C; Ryan C; Löthman H; Drudge-Coates L; Costa L
Clin J Oncol Nurs; 2009 Dec; 13(6):701-10. PubMed ID: 19948468
[TBL] [Abstract][Full Text] [Related]
18. Evaluating bone metastases.
Albert K
Clin J Oncol Nurs; 2007 Apr; 11(2):193-7. PubMed ID: 17573268
[No Abstract] [Full Text] [Related]
19. Cancer-induced bone disease.
Drudge-Coates L; Turner B
Nurs Stand; 2013 Jan 9-15; 27(19):48-56; quiz 57. PubMed ID: 23427627
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors.
Scher HI; Yagoda A
Am J Med; 1987 Feb; 82(2A):6-28. PubMed ID: 3548343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
